Early human trials in people with obesity found that daily AOD9604 was well tolerated and had a safety profile similar to placebo, with no major effects on glucose metabolism or IGF1, though weightloss results were modest and inconsistent
Its safety, efficacy, and pharmacological profile in humans have not been established
Importantly, serum B12 levels can be misleadingly normal or even elevated in chronic liver disease due to increased levels of binding proteins (such as haptocorrin) and reduced clearance, meaning that total B12 measurements may not accurately reflect tissue B12 status or functional deficiency
Fusce molestie elit a loremos tempus scelerisque blandit tortor cursus
(5) K.Skrlec et al (2018) Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities Applied Microbiology and Biotechnology, 06 September 2018, Volume 102, pages 101031011